

# Javier Escalada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/420222/publications.pdf>

Version: 2024-02-01

54  
papers

2,140  
citations

430874

18  
h-index

233421

45  
g-index

62  
all docs

62  
docs citations

62  
times ranked

3400  
citing authors

#	ARTICLE	IF	CITATIONS
1	Basal insulin analogues in people with diabetes and chronic kidney disease. <i>Diabetic Medicine</i> , 2022, 39, e14679.	2.3	1
2	High plasma and lingual uroguanylin as potential contributors to changes in food preference after sleeve gastrectomy. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 155119.	3.4	4
3	Transient elastography and serum markers of liver fibrosis associate with epicardial adipose tissue and coronary artery calcium in NAFLD. <i>Scientific Reports</i> , 2022, 12, 6564.	3.3	7
4	“Obesities”™: Position statement on a complex disease entity with multifaceted drivers. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13811.	3.4	20
5	Executive summary on the treatment of type 2 diabetes mellitus in elderly or frail individuals. 2022 update of the 2018 consensus document “Treatment of type 2 diabetes mellitus in the elderly” Revista Clínica Española, 2022, .	0.5	0
6	Prevention of Cardiorenal Complications with Sodium-Glucose Cotransporter Type 2 Inhibitors: A Narrative Review. <i>Diabetes Therapy</i> , 2022, 13, 5-17.	2.5	6
7	Impact on the Nutritional Status and Inflammation of Patients with Cancer Hospitalized after the SARS-CoV-2 Lockdown. <i>Nutrients</i> , 2022, 14, 2754.	4.1	3
8	Optimization of pseudo-continuous arterial spin labeling for renal perfusion imaging. <i>Magnetic Resonance in Medicine</i> , 2021, 85, 1507-1521.	3.0	16
9	Promoting exercise, reducing sedentarism or both for diabetes prevention: The “Seguimiento Universidad De Navarra”(SUN) cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 411-419.	2.6	6
10	¿PUEDE LA PANDEMIA DE COVID-19 SER UNA OPORTUNIDAD DE MEJORA PARA NUESTRA ACTIVIDAD ASISTENCIAL, FORMATIVA Y DE INVESTIGACIÓN?. <i>Endocrinología y Nutrición (English Ed)</i> , 2021, 68, 79-81.	0.2	0
11	Resting Energy Expenditure Is Not Altered in Children and Adolescents with Obesity. Effect of Age and Gender and Association with Serum Leptin Levels. <i>Nutrients</i> , 2021, 13, 1216.	4.1	8
12	Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2040.	2.4	6
13	Ultra-processed foods and type-2 diabetes risk in the SUN project: A prospective cohort study. <i>Clinical Nutrition</i> , 2021, 40, 2817-2824.	5.0	50
14	Physical Activity Intensity and Type 2 Diabetes: Isotemporal Substitution Models in the “Seguimiento Universidad de Navarra”(SUN) Cohort. <i>Journal of Clinical Medicine</i> , 2021, 10, 2744.	2.4	4
15	Role of ANGPTL8 in NAFLD Improvement after Bariatric Surgery in Experimental and Human Obesity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12945.	4.1	6
16	Alterations in SLC4A2, SLC26A7 and SLC26A9 Drive Acid-Base Imbalance in Gastric Neuroendocrine Tumors and Uncover a Novel Mechanism for a Co-Occurring Polyautoimmune Scenario. <i>Cells</i> , 2021, 10, 3500.	4.1	9
17	Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. <i>Advances in Therapy</i> , 2020, 37, 3863-3877.	2.9	7
18	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 975-985.	0.4	3

#	ARTICLE	IF	CITATIONS
19	What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 587-589.	0.3	0
20	Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. <i>Diabetes Therapy</i> , 2019, 10, 1893-1907.	2.5	2
21	Mechanisms Underlying Type 2 Diabetes Remission After Metabolic Surgery. <i>Frontiers in Endocrinology</i> , 2019, 10, 641.	3.5	45
22	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2019, 11, 677.	4.1	137
23	Discriminatory ability of anthropometric measurements of central fat distribution for prediction of post-prandial hyperglycaemia in patients with normal fasting glucose: the DICAMANO Study. <i>Journal of Translational Medicine</i> , 2019, 17, 48.	4.4	6
24	Documento de abordaje integral de la diabetes tipo 2. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 443-458.	0.3	24
25	High Body Adiposity Drives Glucose Intolerance and Increases Cardiovascular Risk in Normoglycemic Subjects. <i>Obesity</i> , 2018, 26, 672-682.	3.0	9
26	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 683-697.	2.4	19
27	Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. <i>Diabetes Therapy</i> , 2018, 9, 2043-2053.	2.5	6
28	Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild to moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2860-2868.	4.4	20
29	Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?. <i>European Journal of Internal Medicine</i> , 2017, 41, 74-78.	2.2	30
30	Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1810-1817.	3.4	73
31	Lessons from 11C-dihydrotetrabenazine imaging in a xenograft mouse model of rat insulinoma: is PET imaging of pancreatic beta cell mass feasible?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 447-455.	0.7	1
32	Percepción de profesionales sobre los circuitos asistenciales del paciente hipertenso o diabético entre la atención primaria y atención especializada. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2016, 63, 4-12.	0.8	2
33	Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: A survey research. <i>Diabetes Research and Clinical Practice</i> , 2016, 122, 46-53.	2.8	19
34	Outcomes and healthcare resource utilization associated with medically attended hypoglycemia in older patients with type 2 diabetes initiating basal insulin in a US managed care setting. <i>Current Medical Research and Opinion</i> , 2016, 32, 1557-1565.	1.9	8
35	Hypoglycemic Syndrome without Hyperinsulinemia. A Diagnostic Challenge. <i>Endocrine Pathology</i> , 2016, 27, 50-54.	9.0	6
36	Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. <i>Diabetes Therapy</i> , 2015, 6, 173-185.	2.5	23

#	ARTICLE	IF	CITATIONS
37	Cardiometabolic Profile Related to Body Adiposity Identifies Patients Eligible for Bariatric Surgery More Accurately than BMI. <i>Obesity Surgery</i> , 2015, 25, 1594-1603.	2.1	8
38	GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK. <i>Diabetes</i> , 2014, 63, 3346-3358.	0.6	422
39	¿Existe mayor riesgo de diabetes gestacional en pacientes con disfunción tiroidea autoinmune?. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2014, 61, 377-381.	0.8	6
40	Consensus document for the detection and management of chronic kidney disease. <i>Nefrologia</i> , 2014, 34, 243-62.	0.4	61
41	Cardiotrophin 1 protects beta cells from apoptosis and prevents streptozotocin-induced diabetes in a mouse model. <i>Diabetologia</i> , 2013, 56, 838-846.	6.3	19
42	Clinical Usefulness of a New Equation for Estimating Body Fat. <i>Diabetes Care</i> , 2012, 35, 383-388.	8.6	177
43	Respuesta a Relimpio et al.. <i>Avances En Diabetología</i> , 2012, 28, 121-122.	0.1	4
44	Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. <i>International Journal of Obesity</i> , 2012, 36, 286-294.	3.4	427
45	Body Adiposity and Type 2 Diabetes: Increased Risk With a High Body Fat Percentage Even Having a Normal BMI. <i>Obesity</i> , 2011, 19, 1439-1444.	3.0	202
46	La prueba de tiroglobulina tras hormona estimulante de la tiroides recombinante modifica la estrategia del seguimiento del cáncer diferenciado de tiroides. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2006, 53, 543-549.	0.8	0
47	Differential regulation of gonadotropins and glycoprotein hormone $\beta$ -subunit by IGF-I in anterior pituitary cells from male rats. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 670-675.	3.3	7
48	Mechanisms of Reduced Body Growth in the Pubertal Feminized Male Rat: Unbalanced Estrogen and Androgen Action on the Somatotropic Axis. <i>Pediatric Research</i> , 2000, 48, 96-103.	2.3	4
49	Regulation of Gonadal and Somatotropic Axis by Chronic Intraventricular Infusion of Insulin-Like Growth Factor 1 Antibody at the Initiation of Puberty in Male Rats. <i>Neuroendocrinology</i> , 1999, 69, 408-416.	2.5	37
50	Regulation of Growth Hormone (GH) Gene Expression and Secretion During Pregnancy and Lactation in the Rat: Role of Insulin-Like Growth Factor-I, Somatostatin, and GH-Releasing Hormone. <i>Endocrinology</i> , 1997, 138, 3435-3443.	2.8	31
51	Regulation of Growth Hormone (GH) Gene Expression and Secretion During Pregnancy and Lactation in the Rat: Role of Insulin-Like Growth Factor-I, Somatostatin, and GH-Releasing Hormone. <i>Endocrinology</i> , 1997, 138, 3435-3443.	2.8	8
52	Neoplastic Colonic Polyps in Acromegaly. <i>Hormone and Metabolic Research</i> , 1994, 26, 609-610.	1.5	29
53	Normal calcitonin response to pentagastrin stimulation in patients with chronic renal failure. <i>European Journal of Endocrinology</i> , 1993, 129, 39-41.	3.7	11
54	SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D. <i>Diabetes Therapy</i> , 0, , .	2.5	0